Earnings Releases·Nov 5, 2026, 7:02 AM ET

Apyx Medical Corporation — Third Quarter 2026 Earnings Summary

Total revenue rose 9% year-over-year to $14.0 million, driven by a 17% surge in Surgical Aesthetics sales, while OEM revenue declined 42% to $1.1 million; net loss narrowed to $1.8 million ($0.04/share) from $2.0 million in the prior year, with adjusted EBITDA turning positive at $0.4 million.
Reaffirmed full-year 2026 revenue guidance of $59.0–$60.0 million and updated operating expense guidance downward to $41.0–$42.5 million, reflecting a strategic pivot toward the Surgical Aesthetics segment which is projected to generate $54.0–$55.0 million for the year.
Commercially launched the reusable power liposuction handpiece for the AYON system following positive early surgeon feedback and FDA clearance, supported by clinical data showing 30% greater elastin fiber density and 34% less inflammation compared to controls.
Ended the quarter with $25.8 million in cash and cash equivalents and $35.6 million in long-term debt, while net cash used in operating activities improved significantly to $1.6 million from $3.5 million in the prior year period.